Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01755858 · ClinicalTrials.gov registry record · Phase 1
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
A Phase 1 study, sponsored by Stealth BioTherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01755858 is a Phase 1 study that was terminated before completion, run by Stealth BioTherapeutics. The registered enrollment target is 16 participants.
The verdict
NCT01755858, a Phase 1 study, was terminated before completion, sponsored by Stealth BioTherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with Atherosclerotic Renal Artery Stenosis (ARAS), who are undergoing percutaneous transluminal angioplasty of the renal artery (PTRA).
Interventions
- DRUG Placebo
- DRUG Bendavia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01755858
The ClinicalTrials.gov registry entry for NCT01755858 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01755858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01755858 about?
NCT01755858 is a clinical study titled "Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery". This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with Atherosclerotic Renal Artery Stenosis (ARAS), who are ...
What is the current status of trial NCT01755858?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-12. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01755858?
The interventions under investigation include: Placebo (DRUG), Bendavia (DRUG).
Who is sponsoring clinical trial NCT01755858?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.